Genome Surveillance and Vaccine Development for SARS-CoV2 Virus in East Indonesia

Publish : 2020 | -

The “Genome surveillance and vaccine development for SARS-CoV2 virus in East Indonesia” research is an international collaborative research studying the genomic data of SARS-CoV2 virus circulating in Eastern part of Indonesia. Whole genomic sequencing will be performed in samples collected in dr. Soetomo General Academic Hospital Surabaya, Institute of Tropical Disease Universitas Airlangga (ITD), and National Institute Health Research and Development, Ministry of Health Indonesia (NIH-HRD, MOH) who served as referral laboratories for SARS-CoV2 PCR examination in eastern Indonesia. Genetic drift, mutation data and genomic surveillance will be studied from collected samples to build Indonesian genome data of SAR-COV2 by Research Center of Bio-molecule Engineering (BIOME), Universitas Airlangga. Based from SARS-CoV2 sequencing analysis data available, construction of non replicating virus vector that can be use for vaccine development candidate will be made. Collaborative study with Faculty of Biology, Medicine and Health, The University of Manchester, United Kingdom will be performed to develop sets of non-replicating virus constructs bearing SARSCoV2 epitope by recombinant virus technology using Adenovirus(AV) or gutted adenoassociated viruses (AAV) as carrier. After the non-replicating SARS-CoV2 virus vector suitable for vaccine candidate is established, production of the virus vector will be conducted in ITD through capacity building process from Manchester University. Animal testing will be studied with several stages to test the antibody production and virus immunity. Following animal testing results, a phase I clinical trial on human will be conducted in dr. Soetomo General Academic Hospital. As the outputs of this collaborative research are international publication in Q1 Journals about Indonesian SAR-CoV2 virus genome/ genomic surveillance and development of SAR-CoV2 vaccine prototype, sequence library of Indonesian virus in Global Initiative on Sharing All Influenza Data (GISAID), capacity building for Indonesia research team on constructing recombinant virus vector vaccine technology, and giving scientific basis for mass production of SARS-COV2 vaccine with possible collaboration with pharma industry.

Visit Original